November 07, 2017
Author: Peter Poechlauer, Ph.D.

The need for new medicines for previously untreatable diseases creates new challenges for drug development. When a new lead is generated, small amounts of preclinical material are needed and produced—at any cost—to demonstrate a first proof of concept. In subsequent development phases, however, the pharmaceutical company must quickly develop an acceptable and scalable synthesis of complex new drug candidates to meet accelerating timelines and rapidly move the molecule through clinical development.

In this webcast, you will learn the many pieces to the development puzzle that need to be put together when taking a new chemical entity to market, how disregarding these pieces may lead to product failure even in late stages of development and potential challenges facing a complex molecule and what a company needs to consider about each one while moving through development.